TR200601092T1 - İrbesartan etkin maddesi içeren yeni oral farmasötik formülasyonlar. - Google Patents

İrbesartan etkin maddesi içeren yeni oral farmasötik formülasyonlar.

Info

Publication number
TR200601092T1
TR200601092T1 TR2006/01092T TR200601092T TR200601092T1 TR 200601092 T1 TR200601092 T1 TR 200601092T1 TR 2006/01092 T TR2006/01092 T TR 2006/01092T TR 200601092 T TR200601092 T TR 200601092T TR 200601092 T1 TR200601092 T1 TR 200601092T1
Authority
TR
Turkey
Prior art keywords
active ingredient
pharmaceutical formulations
irbesartan
formulations containing
oral pharmaceutical
Prior art date
Application number
TR2006/01092T
Other languages
English (en)
Inventor
Uslu Abdullah
Original Assignee
Nobel �La� Sanay� Ve T�Caret A�.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nobel �La� Sanay� Ve T�Caret A�. filed Critical Nobel �La� Sanay� Ve T�Caret A�.
Publication of TR200601092T1 publication Critical patent/TR200601092T1/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Bu buluş irbesartan etken maddesini içeren ve bu etken maddenin oral yolla alınmasını sağlayan yenifarmasötik dozaj formlarını hazırlamak için geliştirilen yeni yöntem ile ilgilidir. Geliştirilen buformülasyon ile irbesartamn dissolüsyon özelliklerine üstünlük kazandırılmıştır.
TR2006/01092T 2003-09-18 2004-09-16 İrbesartan etkin maddesi içeren yeni oral farmasötik formülasyonlar. TR200601092T1 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2003/01553A TR200301553A1 (tr) 2003-09-18 2003-09-18 İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar

Publications (1)

Publication Number Publication Date
TR200601092T1 true TR200601092T1 (tr) 2006-08-21

Family

ID=34311482

Family Applications (2)

Application Number Title Priority Date Filing Date
TR2003/01553A TR200301553A1 (tr) 2003-09-18 2003-09-18 İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
TR2006/01092T TR200601092T1 (tr) 2003-09-18 2004-09-16 İrbesartan etkin maddesi içeren yeni oral farmasötik formülasyonlar.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TR2003/01553A TR200301553A1 (tr) 2003-09-18 2003-09-18 İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar

Country Status (3)

Country Link
EP (1) EP1670461A1 (tr)
TR (2) TR200301553A1 (tr)
WO (1) WO2005025566A1 (tr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602006013261D1 (de) * 2006-01-09 2010-05-12 Krka D D Irbesartan enthaltende feste Zubereitung
EP1923053A1 (en) 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
CN101011393B (zh) * 2007-02-16 2010-10-06 广州柏赛罗药业有限公司 厄贝沙坦胃内滞留型缓释药物组合物
DE102007055341A1 (de) * 2007-11-19 2009-05-20 Bayer Animal Health Gmbh Stabilisierung öliger Suspensionen enthaltend hydrophobe Kieselsäuren
PL2065035T3 (pl) 2007-11-28 2011-02-28 Lesvi Laboratorios Sl Preparaty farmaceutyczne zawierające irbesartan
WO2011141783A2 (en) 2010-04-13 2011-11-17 Micro Labs Limited Pharmaceutical composition comprising irbesartan
DE102011108762A1 (de) * 2011-07-28 2013-01-31 Stada Arzneimittel Ag Verpresste feste pharmazeutische Zusammensetzung, umfassend amorphes partikuläres Valsartan als Wirkstoff
CN107028912B (zh) * 2017-05-31 2019-03-19 珠海润都制药股份有限公司 一种厄贝沙坦胶囊的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270317A (en) * 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
US5994348A (en) * 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
FR2831446B1 (fr) * 2001-10-26 2004-03-05 Sanofi Synthelabo Utilisation de l'irbesartan pour la preparation de medicaments utiles pour la prevention ou le traitement de l'hypertension pulmonaire
CN1199641C (zh) * 2002-10-24 2005-05-04 王登之 一种用于治疗高血压的复方厄贝沙坦胶囊

Also Published As

Publication number Publication date
WO2005025566A1 (en) 2005-03-24
EP1670461A1 (en) 2006-06-21
TR200301553A1 (tr) 2005-10-21

Similar Documents

Publication Publication Date Title
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
BR0112311A (pt) Compostos e composições para liberar agentes ativos, forma de dosagem unitária, método para preparar ditas composições e seu uso
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
BR0306870A (pt) Composição farmacêutica oral, e, método para preparar a mesma
UY27908A1 (es) Formulaciones y formas de dosificación para la administración controlada de topiramato
CY1111698T1 (el) Συνδυασμος που περιλαμβανει εναν ανταγωνιστη υποδοχεα ατ1 και εναν ενισχυτη εκκρισης ινσουλινης ή εναν ευαισθητοποιητη ινσουλινης
CY1113462T1 (el) Μορφη δοσολογιας περιεχουσα παντοπραζολη ως δραστικο συστατικο
DK0954314T3 (da) Doseringsformer til bedring af mandlig erektionsdefekt
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
SE0401342D0 (sv) Therapeutic compounds
DE50203456D1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
MXPA05007609A (es) Antagonista de un receptor sensible al calcio.
NO20062051L (no) Farmasoytisk virkestoffinneholdende formulering med belegg
SE0302573D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0301701D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0301699D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302570D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
TR200301553A1 (tr) İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
SE0302572D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
EA200701409A1 (ru) Новая композиция
NO20064808L (no) Orale matrixformuleringer med licarbazepin
EA200601015A1 (ru) Пероральные композиции дезоксипеганина и их применение